Abstract
Background: Chemoradiotherapy (CRT) is an effective modality for stage I esophageal squamous cell carcinoma (ESCC). However, salvage treatments are often required even if complete response (CR) has been achieved. To this end, it is important to accurately diagnose lymph node or other organ metastatic recurrences. Note that lymph node enlargements (except metastatic recurrence) are often detected during the follow-up period after CRT. The purpose of this study was to elucidate the clinical characteristics of lymph node enlargement after CRT.Methods: In this retrospective cohort study, patients diagnosed with stage I (T1 [submucosal invasion] N0M0) ESCC were treated with cisplatin and 5-fluorouracil concurrently with radiotherapy. A total of 55 patients were enrolled in the study from February 2006 to August 2011.Results: The median follow-up period was 46 months. The 3-year overall and progression-free survival rates were 90.7% and 71.2%, respectively, and the CR rate was 87.2% (48/55). Nine of the 48 CR patients were finally diagnosed with recurrences, including 7 lymph node metastases and 2 local recurrences. Lymph node enlargement was initially identified in 20 of the total 55 patients during the follow-up; 9 patients were finally diagnosed with lymph node recurrence, whereas 11 patients had benign reactive lymph node enlargement.Conclusion: The present study demonstrated the high incidence of enlarged lymph nodes after CRT for stage I ESCC. It is important to accurately distinguish between benign lymph node enlargement and recurrent lymph nodes to avoid unnecessary salvage treatments.
| Original language | English |
|---|---|
| Article number | 706 |
| Journal | BMC Cancer |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2014 Sep 24 |
| Externally published | Yes |
Fingerprint
Keywords
- Chemoradiotherapy
- Esophageal carcinoma
- Lymph node enlargement
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Genetics
- Medicine(all)
Cite this
Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma. / Hayashi, Yoshito; Nishida, Tsutomu; Tsujii, Masahiko; Tsutsui, Shusaku; Yamamoto, Katsumi; Isohashi, Fumiaki; Yamasaki, Makoto; Miyata, Hiroshi; Kato, Motohiko; Yamada, Takuya; Shinzaki, Shinichiro; Iijima, Hideki; Ogawa, Kazuhiko; Doki, Yuichiro; Takehara, Tetsuo.
In: BMC Cancer, Vol. 14, No. 1, 706, 24.09.2014.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
AU - Hayashi, Yoshito
AU - Nishida, Tsutomu
AU - Tsujii, Masahiko
AU - Tsutsui, Shusaku
AU - Yamamoto, Katsumi
AU - Isohashi, Fumiaki
AU - Yamasaki, Makoto
AU - Miyata, Hiroshi
AU - Kato, Motohiko
AU - Yamada, Takuya
AU - Shinzaki, Shinichiro
AU - Iijima, Hideki
AU - Ogawa, Kazuhiko
AU - Doki, Yuichiro
AU - Takehara, Tetsuo
PY - 2014/9/24
Y1 - 2014/9/24
N2 - Background: Chemoradiotherapy (CRT) is an effective modality for stage I esophageal squamous cell carcinoma (ESCC). However, salvage treatments are often required even if complete response (CR) has been achieved. To this end, it is important to accurately diagnose lymph node or other organ metastatic recurrences. Note that lymph node enlargements (except metastatic recurrence) are often detected during the follow-up period after CRT. The purpose of this study was to elucidate the clinical characteristics of lymph node enlargement after CRT.Methods: In this retrospective cohort study, patients diagnosed with stage I (T1 [submucosal invasion] N0M0) ESCC were treated with cisplatin and 5-fluorouracil concurrently with radiotherapy. A total of 55 patients were enrolled in the study from February 2006 to August 2011.Results: The median follow-up period was 46 months. The 3-year overall and progression-free survival rates were 90.7% and 71.2%, respectively, and the CR rate was 87.2% (48/55). Nine of the 48 CR patients were finally diagnosed with recurrences, including 7 lymph node metastases and 2 local recurrences. Lymph node enlargement was initially identified in 20 of the total 55 patients during the follow-up; 9 patients were finally diagnosed with lymph node recurrence, whereas 11 patients had benign reactive lymph node enlargement.Conclusion: The present study demonstrated the high incidence of enlarged lymph nodes after CRT for stage I ESCC. It is important to accurately distinguish between benign lymph node enlargement and recurrent lymph nodes to avoid unnecessary salvage treatments.
AB - Background: Chemoradiotherapy (CRT) is an effective modality for stage I esophageal squamous cell carcinoma (ESCC). However, salvage treatments are often required even if complete response (CR) has been achieved. To this end, it is important to accurately diagnose lymph node or other organ metastatic recurrences. Note that lymph node enlargements (except metastatic recurrence) are often detected during the follow-up period after CRT. The purpose of this study was to elucidate the clinical characteristics of lymph node enlargement after CRT.Methods: In this retrospective cohort study, patients diagnosed with stage I (T1 [submucosal invasion] N0M0) ESCC were treated with cisplatin and 5-fluorouracil concurrently with radiotherapy. A total of 55 patients were enrolled in the study from February 2006 to August 2011.Results: The median follow-up period was 46 months. The 3-year overall and progression-free survival rates were 90.7% and 71.2%, respectively, and the CR rate was 87.2% (48/55). Nine of the 48 CR patients were finally diagnosed with recurrences, including 7 lymph node metastases and 2 local recurrences. Lymph node enlargement was initially identified in 20 of the total 55 patients during the follow-up; 9 patients were finally diagnosed with lymph node recurrence, whereas 11 patients had benign reactive lymph node enlargement.Conclusion: The present study demonstrated the high incidence of enlarged lymph nodes after CRT for stage I ESCC. It is important to accurately distinguish between benign lymph node enlargement and recurrent lymph nodes to avoid unnecessary salvage treatments.
KW - Chemoradiotherapy
KW - Esophageal carcinoma
KW - Lymph node enlargement
UR - http://www.scopus.com/inward/record.url?scp=84907742261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907742261&partnerID=8YFLogxK
U2 - 10.1186/1471-2407-14-706
DO - 10.1186/1471-2407-14-706
M3 - Article
VL - 14
JO - BMC Cancer
JF - BMC Cancer
SN - 1471-2407
IS - 1
M1 - 706
ER -